HUMAN LEUKEMIA ANTIGENS: ISOLATION AND CHARACTERIZATION

白血病和淋巴瘤细胞的免疫学特征 促进调查，旨在提高我们的理解， 人类白血病和淋巴瘤异质性和病理生理学。 我们 已经进行了研究，以表征白血病和淋巴瘤细胞表面 用体细胞杂交产生的单克隆抗体抗原 技术. 这些抗体已被证明可用于定义 白血病和淋巴瘤细胞的异质性和谱系， 定义它们的分化状态。 唯一的识别 通过血清学技术检测细胞表面抗原， 多种T、B和髓细胞白血病的诊断和鉴别 彼此之间。 此外，这些独特的细胞表面轮廓具有 允许发展和理解的关系， 白血病细胞向正常T、B和髓样细胞分化的状态。 白血病细胞的抗体使白血病的快速发展成为可能。 用于白血病的分类和表征的测定， 更重要的是，识别同质性淋巴瘤， 白血病和淋巴瘤表型导致这些试剂用于 个体恶性肿瘤的诊断和 通过自体免疫治疗这些疾病的适当抗体 和错配移植 证明抗CALLA（J5）是 与大多数非T细胞白血病和抗B1反应 大多数B细胞淋巴瘤鼓励使用这些抗体， 自体骨髓移植中的骨髓净化。 长期 联合骨髓净化和 积极的化疗 在此期间，取得了很大进展。 在过去的一年中，在利用特异性单克隆抗体， 白血病和淋巴瘤的诊断，更重要的是， 这些疾病的具体治疗。 （L8）

The immunologic characterization of leukemic and lymphoma cells has facilitated investigations designed to improve our understanding of the heterogeneity and pathophysiology of human leukemias and lymphomas. We have undertaken studies to characterize leukemic and lymphoma cell surface antigens with monoclonal antibodies produced by somatic cell hybridization techniques. These antibodies have proven useful for the definition of both the heterogeneity and lineage of leukemia and lymphoma cells and in defining their states of differentiation. The identification of unique cell surface antigens by serologic techniques has allowed for the rapid diagnosis and distinction of a variety of T, B, and myeloid cell leukemias from one another. Moreover, these unique cell surface profiles have permitted the development and an understanding of the relationship of the leukemic cell to states of normal T, B, and myeloid cell differentiation. The antibodies to leukemic cells have permitted the development of rapid assays for the classification and characterization of leukemias and lymphomas in man. More importantly, the identification of homogeneous leukemic and lymphoma phenotypes has led to the use of these reagents in both the diagnosis of individual malignancies and the selection of appropriate antibodies for the treatment of these disorders by autologous and mismatched transplantation. The demonstration that anti-CALLA (J5) was reactive with the majority of non-T cell leukemias and anti-Bl was reactive with most B-cell lymphomas has encouraged the use of these antibodies in marrow cleansing in autologous bone marrow transplantation. Long-term remissions have been obtained with a combination of bone marrow cleanup and aggressive chemotherapy. Thus, considerable progress has been made during the past year in the utilization of specific monoclonal antibodies for the diagnosis of leukemias and lymphomas and, more importantly, for the specific therapy of these diseases. (L8)